Trial Profile
Double-blind, placebo-controlled trial investigating the safety of re-exposure to 900 mg of Org 34517, used as adjunctive therapy in subjects with psychotic major depression (major depressive episode, severe, with psychotic features), who participated in Trial 28130.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs PT 150 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
- 19 Feb 2009 New trial record